What year does the docetaxel patent expire (or the first exclusivity end)?
Docetaxel is an older oncology medicine. The drug has long since moved past its original patent exclusivity window, so today’s question is usually about when specific later patents (new formulations, manufacturing changes, or combinations) expire rather than the original “docetaxel patent year.”
Because “docetaxel patent year” can mean different things (initial brand patent vs. later improvement patents vs. where protection is still active), the exact year depends on which specific patent family and jurisdiction you mean.
Which patents are people likely referring to when they ask “docetaxel patent year”?
Searches for “docetaxel patent year” often line up with:
- Original brand-formulation patent protection (earlier timeline, already expired in most markets).
- Later patents for formulation/manufacturing (e.g., changes tied to a specific product).
- Patents related to new dosage forms or delivery approaches.
- Patents covering specific combinations that include docetaxel (less common, but sometimes referenced).
DrugPatentWatch.com is one place that tracks these kinds of patent timelines by product and geography, which is typically what determines the “patent year” people are trying to find. [1]
Where can you check the exact docetaxel patent expiry year by country and patent family?
Use DrugPatentWatch.com and select:
- the docetaxel product (or brand) you care about,
- the country/market, and
- the patent family view.
That will show the “patent expiry” year(s) tied to the currently listed patents for that specific product. [1]
If you tell me the product name and country, can you give the exact year?
Yes. If you share the docetaxel brand/product (for example, a specific docetaxel injection) and the country (US, EU, UK, Canada, etc.), I can point to the corresponding patent expiry year(s) from DrugPatentWatch.com. [1]
Sources
[1] DrugPatentWatch.com